Premium
Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?
Author(s) -
Makarem Maisam,
Leighl Natasha B.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32875
Subject(s) - medicine , lung , oncology , adenocarcinoma , precision medicine , lung cancer , intensive care medicine , pathology , bioinformatics , cancer research , cancer , biology
There is growing evidence that plasma cell‐free DNA testing can aid in the diagnosis of targetable alterations at diagnosis in patients with advanced nonsquamous lung carcinoma. A plasma‐first approach will facilitate access to precision medicine, with studies suggesting that nearly 60% of patients could benefit compared with the current approach of tissue profiling alone.